Auron Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aurontx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Phase 1
Recruiting
- Conditions
- Relapsed Acute Myeloid Leukemia (AML)Refractory Acute Myeloid Leukemia (AML)Relapsed/Refractory AMLRelapsed Myelodysplastic SyndromesRefractory Myelodysplastic SyndromesRelapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Auron Therapeutics, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT06846606
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
News
No news found